… About the PQ-110-001 Phase 1/2 trial PQ-110-001 was an open-label trial designed to enroll children (over six years of age) and adults who have LCA10 due to one or two copies of the p.Cys998X mutation in the CEP290 gene. A total … period and eligible patients are being given the option to participate in Insight, an open-label extension …
… perception de la lumière (MVAC> 3,0 LogMAR) au départ, la population étudiée dans le cadre d' Illuminate était plus … d'acuité visuelle de l'Early Treatment of Diabetic Retinopathy Study (ETDRS ou Étude sur le traitement précoce de la rétinopathie diabétique) et le Test de vision rudimentaire de …
LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the appointment of Dr.
… NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a biopharmaceutical company dedicated to changing lives through … In addition, ProQR has granted the underwriters a 30-day option to purchase up to 1,363,636 additional ordinary shares … dominant retinitis pigmentosa. Based on our unique proprietary RNA repair platform technologies we are growing …
… NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a biopharmaceutical company dedicated to changing lives through … In addition, ProQR has granted the underwriters a 30-day option to purchase up to 862,500 additional ordinary shares … for the offering. Kempen & Co is acting as the Company’s European financial advisor in relation to this offering. A …
… NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through … offering, ProQR has granted the underwriters a 30-day option to purchase up to 745,471 additional ordinary shares … as cystic fibrosis, Leber’s congenital amaurosis 10 and dystrophic epidermolysis bullosa. Based on our unique …
… lives through transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform, today … addition, ProQR expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the offering … cash and cash equivalents, to primarily fund research and development and clinical development to support the …
… addition, ProQR has granted the underwriters a 30-day option to purchase up to 2,076,923 additional ordinary shares … the offering has been filed with the SEC. When available, copies of the final prospectus supplement and the … syndrome and retinitis pigmentosa. Based on our unique proprietary RNA repair platform technologies we are growing …